Aid in diagnosis and classification of hematopoietic neoplasms presenting with prominent eosinophilia. Does not detect rearrangements associated with chronic myelogenous leukemia. Eosinophilia is often a presenting feature, but not invariably so. Specific genetic alterations have served as a basis for targeted treatment approaches that have dramatically altered clinical outcome in some groups of patients.
- Bone Marrow: Transfer 3 mL bone marrow to a Green (Sodium Heparin). (Min: 1 mL)
- Whole Blood: Transport 5 mL whole blood. (Min: 2 mL)
- Sample collection: Non-diluted bone marrow aspirate. Collect in a sodium heparinized Vacutainer.
- Specimen preparation: Do not freeze or expose to extreme temperatures.
- Bone Marrow: Transfer 3 mL bone marrow to a Green (Sodium Heparin). (Min: 1 mL)
- Whole Blood: Transport 5 mL whole blood. (Min: 2 mL)
- Storage/Transport Temperature: Room temperature.
- Unacceptable Conditions: Frozen specimens. Clotted specimens.
- Remarks:
- Stability: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Fluorescence in situ Hybridization (FISH)
Sample received to report Turnaround time (TAT)
3 working days
————-
Interpretive Data
Probes include: PDGFRA break-apart, PDGFRB break-apart, FGFR1 break-apart, CBFB inv(16)
The most recent WHO classification of Tumours of Hematopoietic and Lymphoid Tissues (Revised 5th edition) is used for interpretation criteria for evaluation.
Resources
- Additional Technical Information
- Test Request Form
Sample Reports
- Enhanced Report
- See report